May 17, 2017 / 4:38 PM / 3 months ago

BRIEF-German Merck's Glucophage receives label extension in UK

May 17 (Reuters) - Merck Kgaa

* Merck's Glucophage® sustained release formulation, metformin, receives label extension for patients at high risk of type 2 diabetes in UK

* Glucophage authorised in UK for reduction in risk or delay of onset of type 2 diabetes in adult, overweight patients with impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG), and/or increased glycated hemoglobin (HbA1c), when intensive lifestyle changes for 3 to 6 months have failed

* Merck has already received authorisation for this indication in several countries around the world Further company coverage: (Reporting By Georgina Prodhan)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below